

Package leaflet: Information for the user
Pirfenidone MSN 267 mg film-coated tablets
Pirfenidone MSN 801 mg film-coated tablets
Pirfenidone

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Keep this leaflet. You may need to read it again.

- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Pirfenidone MSN is and what it is used for
2. What you need to know before you take Pirfenidone MSN
3. How to take Pirfenidone MSN
4. Possible side effects
5. How to store Pirfenidone MSN
6. Contents of the pack and other information

1 What Pirfenidone MSN is and what it is used for

Pirfenidone MSN contains the active substance pirfenidone and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in adults.

IPF is a condition in which the tissues in your lungs become swollen and scarred over time, and as a result makes it difficult to breathe deeply. This makes it hard for your lungs to work properly. Pirfenidone MSN helps to reduce scarring and swelling in the lungs, and helps you breathe better.

2 What you need to know before you take Pirfenidone MSN

Do not take Pirfenidone MSN

- if you are allergic to pirfenidone or any of the other ingredients of this medicine (listed in section 6)
- if you have previously experienced angioedema with pirfenidone, including symptoms such as swelling of the face, lips and/or tongue which may be associated with difficulty breathing or wheezing
- if you are taking a medicine called fluvoxamine (used to treat depression and obsessive compulsive disorder [OCD])
- if you have severe or end stage liver disease
- if you have severe or end stage kidney disease requiring dialysis.

If any of the above affects you, do not take Pirfenidone MSN. If you are unsure ask your doctor or pharmacist.

Warnings and precautions

Talk to your doctor or pharmacist before taking Pirfenidone MSN

- You may become more sensitive to sunlight (photosensitivity reaction) when taking Pirfenidone MSN. Avoid the sun (including sunlamps) whilst taking Pirfenidone MSN. Wear sunblock daily and cover your arms, legs and head to reduce exposure to sunlight (see section 4: Possible side effects).

- You should not take other medicines, such as tetracycline antibiotics (such as doxycycline), which may make you more sensitive to sunlight.
- You should tell your doctor if you suffer from kidney problems
- You should tell your doctor if you suffer from mild to moderate liver problems.
- You should stop smoking before and during treatment with Pirfenidone MSN. Cigarette smoking can reduce the effect of Pirfenidone MSN.
- Pirfenidone MSN may cause dizziness and tiredness. Be careful if you have to take part in activities where you have to be alert and co-ordinated.
- Pirfenidone MSN can cause weight loss. Your doctor will monitor your weight whilst you are taking this medicine.
- Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in association with Pirfenidone MSN treatment. Stop using Pirfenidone MSN and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.

Pirfenidone MSN may cause serious liver problems and some cases have been fatal. You will need a blood test before you start taking Pirfenidone MSN and at monthly intervals for the first 6 months and then every 3 months thereafter whilst you are taking this medicine to check whether your liver is working properly. It is important that you have these regular blood tests for as long as you are taking Pirfenidone MSN.

Children and adolescents

Do not give Pirfenidone MSN to children and adolescents under the age of 18.

Other medicines and Pirfenidone MSN

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

This is especially important if you are taking the following medicines, as they may change the effect of Pirfenidone MSN.

Medicines that may increase side effects of Pirfenidone MSN:

- enoxacin (a type of antibiotic)
- ciprofloxacin (a type of antibiotic)
- amiodarone (used to treat some types of heart disease)
- propafenone (used to treat some types of heart disease)
- fluvoxamine (used to treat depression and obsessive compulsive disorder (OCD)).

Medicines that may reduce how well Pirfenidone MSN works:

- omeprazole (used in the treatment of conditions such as indigestion, gastroesophageal reflux disease)
- rifampicin (a type of antibiotic).

Pirfenidone MSN with food and drink

Do not drink grapefruit juice whilst taking this medicine. Grapefruit may prevent Pirfenidone MSN from working properly.

Pregnancy and breast-feeding

As a precautionary measure, it is preferable to avoid the use of Pirfenidone MSN if you are pregnant, planning to become pregnant, or think you might be pregnant as the potential risks to the unborn child are unknown.

If you are breast-feeding or plan to breast-feed speak to your doctor or pharmacist before taking

Pirfenidone MSN. As it is unknown whether Pirfenidone MSN passes into breast milk, your doctor will discuss the risks and benefits of taking this medicine while breast-feeding if you decide to do so.

Driving and using machines

Do not drive or use machines if you feel dizzy or tired after taking Pirfenidone MSN.

Pirfenidone MSN contains sodium

Pirfenidone MSN contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3 How to take Pirfenidone MSN

Treatment with Pirfenidone MSN should be started and overseen by a specialist doctor experienced in the diagnosis and treatment of IPF.

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Your medicine will usually be given to you in increasing doses as follows:

- for the first 7 days take a dose of 267 mg (1 tablet), 3 times a day with food (a total of 801 mg/day)
- from day 8 to 14 take a dose of 534 mg (2 tablets of 267 mg), 3 times a day with food (a total of 1,602 mg/day)
- from day 15 onwards (maintenance), take a dose of 801 mg (3 tablets of 267 mg or 1 tablet of 801 mg), three times a day with food (a total of 2,403 mg/day).

The recommended maintenance daily dose of Pirfenidone MSN is 801 mg (3 tablets of 267 mg or 1 tablet of 801 mg), three times a day with food, for a total of 2,403 mg/day.

Swallow the tablets whole with a drink of water, during or after a meal to reduce the risk of side effects such as nausea (feeling sick) and dizziness. If symptoms continue, see your doctor.

Dose reduction due to side effects

Your doctor may reduce your dose if you suffer from side effects, such as stomach problems, any skin reactions to sunlight or sun lamps, or significant changes to your liver enzymes.

If you take more Pirfenidone MSN than you should

Contact your doctor, pharmacist or nearest hospital casualty department immediately if you have taken more tablets than you should, and take your medicine with you.

If you forget to take Pirfenidone MSN

If you forget a dose, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose. Each dose should be separated by at least 3 hours. Do not take more tablets each day than your prescribed daily dose.

If you stop taking Pirfenidone MSN

In some situations, your doctor may advise you to stop taking Pirfenidone MSN. If for any reason you have to stop taking Pirfenidone MSN for more than 14 consecutive days, your doctor will restart your treatment with a dose of 267 mg 3 times a day, gradually increasing this to a dose of 801 mg 3 times a day.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking Pirfenidone MSN and seek medical attention immediately if you notice any of the following symptoms or signs

- Swelling of the face, lips and/or tongue, itching, hives, difficulty breathing or wheezing, or feeling faint, which are signs of angioedema, a serious allergic reaction or anaphylaxis.
- Yellowing of the eyes or skin, or dark urine, potentially accompanied by itching of the skin, pain on the upper right side of your stomach area (abdomen), loss of appetite, bleeding or bruising more easily than normal, or feeling tired. These may be signs of abnormal liver function and could indicate liver injury, which is an uncommon side effect of Pirfenidone MSN.
- Reddish non-elevated, or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes. These serious skin rashes can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome or toxic epidermal necrolysis).
- Widespread rash, high body temperature and enlarged lymph nodes (DRESS syndrome or drug hypersensitivity syndrome).

Other side effects may include

Talk to your doctor if you get any side effects.

Very common side effects (may affect more than 1 in 10 people):

- infections of the throat or the airways going into the lungs and/or sinusitis
- feeling sick (nausea)
- stomach problems such as acid reflux, vomiting, and feeling constipated
- diarrhoea
- indigestion or stomach upset
- weight loss
- decreased appetite
- difficulty sleeping
- tiredness
- dizziness
- headache
- shortness of breath
- cough
- aching joints/joint pains.

Common side effects (may affect up to 1 in 10 people):

- bladder infections
- feeling sleepy
- changes in taste
- hot flushes
- stomach problems such as feeling bloated, abdominal pain and discomfort, heart burn and passing wind
- blood tests may show increased levels of liver enzymes
- skin reactions after going out in the sun or using sunlamps
- skin problems such as itchy skin, skin redness or red skin, dry skin, skin rash
- muscle pain
- feeling weak or feeling low in energy
- chest pain
- sunburn.

Uncommon side effects (may affect up to 1 in 100 people)

- Low levels of sodium in the blood. This may cause headache, dizziness, confusion, weakness, muscle cramps or nausea and vomiting
- blood tests may show decrease in white blood cells.

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

HPRÁ Pharmacovigilance

Website: www.hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Pirfenidone MSN

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the bottle label, blister and carton after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Pirfenidone MSN contains

267 mg tablet

The active substance is pirfenidone. Each film-coated tablet contains 267 mg of pirfenidone.

The other ingredients are: cellulose, microcrystalline, croscarmellose sodium, hydroxypropyl cellulose, silica colloidal anhydrous and magnesium stearate.

The film coat consists of polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol 4000 and talc.

801 mg tablet

The active substance is pirfenidone. Each film-coated tablet contains 801 mg of pirfenidone.

The other ingredients are: cellulose, microcrystalline, croscarmellose sodium, hydroxypropyl cellulose, silica colloidal anhydrous and magnesium stearate.

The film coat consists of polyvinyl alcohol-part hydrolyzed, titanium dioxide, macrogol 4000 and talc.

What Pirfenidone MSN looks like and contents of the pack


267 mg tablet

White, oval shaped, film coated tablets debossed with “M” on one side and “PF1” on other side.

The HDPE bottle pack of one bottle containing 90 tablets and two bottles each containing 90 tablets (180 tablets in total).

Pirfenidone MSN 267 mg is available in packs containing 21, 42, 84 or 168 film-coated tablets in plain blisters or in packs available 63 x 1 and 252 x 1 film-coated tablets in perforated unit dose blisters. The multipacks contain 63 (2-week treatment initiation pack 21+42) or 252 (continuation pack 3x84) film-coated tablets.

The 267 mg blister strips containing 63 and 63x1 film-coated tablets are each marked with the following symbols and abbreviated names of the day as a reminder to take a dose three times a day:



801 mg tablet


White, oval shaped, film coated tablets debossed with “M” on one side and “PF3” on other side.

The HDPE bottle pack of one bottle containing 90 tablets.

Pirfenidone MSN 801 mg is available in packs containing 84 film-coated tablets in plain blisters or in packs containing 84 x 1 film-coated tablets in perforated unit dose blister.

The multipack contains 252 (continuation pack 3x84) film-coated tablets.

The 801 mg blisters strips are each marked with the following symbols and abbreviated names of the day as a reminder to take a dose three times a day:



Not all pack sizes may be marketed.

Marketing Authorisation Holder

MSN Labs Europe Limited,
KW20A, Corradino Park,
Paola PLA 3000,
Malta

Manufacturer

Pharmadox Healthcare Limited,
KW20A Kordin Industrial Park, Paola,
PLA3000
Malta

MSN Labs Europe Limited
KW20A Corradino Park, Paola,
PLA3000
Malta

This medicinal product is authorised in the Member States of the European Economic Area under the following names:

The Netherlands	Pirfenidon Vivanta 267 mg filmomhulde tabletten Pirfenidon Vivanta 801 mg filmomhulde tabletten
Germany	Pirfenidon Vivanta 267 mg Filmtabletten Pirfenidon Vivanta 801 mg Filmtabletten

Spain	Pirfenidona Vivanta 267 mg comprimidos recubiertos con película EFG Pirfenidona Vivanta 801 mg comprimidos recubiertos con película EFG
Portugal	Pirfenidona Vivanta
Denmark	Pirfenidone Vivanta
Finland	Pirfenidone Vivanta 267 mg kalvopäällysteiset tabletit Pirfenidone Vivanta 801 mg kalvopäällysteiset tabletit
Norway	Pirfenidone Vivanta
Sweden	Pirfenidone Vivanta 267 mg filmdragerad tablet Pirfenidone Vivanta 801 mg filmdragerad tablet
Italy	Pirfenidone Vivanta 267 mg compresse rivestite con film Pirfenidone Vivanta 801 mg compresse rivestite con film
Cyprus	Pirfenidon MSN 267 mg, film-coated tablets Pirfenidon MSN 801 mg, film-coated tablets
Ireland	Pirfenidone MSN 267 mg film-coated tablets Pirfenidone MSN 801 mg film-coated tablets
Malta	Pirfenidone MSN 267 mg film-coated tablets
Czech Republic	Pirfenidon MSN
Croatia	Pirfenidon MSN 267 mg filmom obložene tablete Pirfenidon MSN 801 mg filmom obložene tablete
Poland	Pirfenidon MSN
Slovenia	Pirfenidon MSN 267 mg filmsko obložene tablete Pirfenidon MSN 801 mg filmsko obložene tablete
Bulgaria	Пирфенидон MSN 267 mg филмирани таблетки Пирфенидон MSN 801 mg филмирани таблетки
Romania	Pirfenidon MSN 267 mg comprimate filmate Pirfenidon MSN 801 mg comprimate filmate
Slovakia	Pirfenidon MSN
Hungary	Pirfenidon MSN 267 mg filmtabletta Pirfenidon MSN 801 mg filmtabletta
Estonia	Pirfenidone MSN
Lithuania	Pirfenidone MSN 267 mg plėvele dengtos tabletės Pirfenidone MSN 801 mg plėvele dengtos tabletės
Latvia	Pirfenidone MSN 267 mg apvalkotās tabletes Pirfenidone MSN 801 mg apvalkotās tabletes

This leaflet was last revised in December 2025.